Skip to main content
Erschienen in: Journal of Gastrointestinal Cancer 1/2017

27.12.2016 | Original Research

Cost Effectiveness of Metal Stents in Relieving Obstructive Jaundice in Patients with Pancreatic Cancer

verfasst von: J. M. Martinez, A. Anene, T. G. K. Bentley, M. J. Cangelosi, L. M. Meckley, J. D. Ortendahl, A. J. Montero

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

ASGE and ESGE guidelines recommend endoscopic metal stent placement for pancreatic carcinoma patients with biliary obstruction, and whose estimated life expectancy is greater than 6 months. Because median overall survival (OS) of metastatic pancreatic adenocarcinoma until recently has been less than 6 months, plastic biliary stents were preferentially placed rather than metal due to the greater upfront cost of the latter. Recent advances in the treatment of metastatic pancreatic cancer have extended median OS beyond the 6-month range. Given this improvement in OS, we performed a cost-effectiveness analysis of initial metal biliary versus plastic stent placement in metastatic pancreatic cancer patients with biliary obstruction.

Methods

A Markov model was developed to predict lifetime costs, quality-adjusted life years (QALYs), and cost effectiveness of metal compared with plastic stents. Adult patients entered the model with locally advanced cancer and underwent endoscopic retrograde cholangiopancreatography (ERCP) with placement of metal or plastic stents. A targeted literature search was conducted to identify published sources, which were used to estimate clinical, cost, utility, and event rate inputs to the model. Results were estimated from the third-party payer perspective in 2012 US dollars per QALY. One-way and probabilistic sensitivity analyses were conducted to assess the impact on model outcomes resulting from uncertainty among inputs.

Results

Our analysis found that initial placement of metal stents was more cost effective than plastic biliary stents with lower overall costs due to lower restenting rates while at the same time associated with a better quality of life. Based on model projections, placement of metal stents could save approximately $1450 per patient over a lifetime, while simultaneously improving quality of life. These findings were robust in sensitivity analyses.

Conclusions

Placement of metal biliary stents at initial onset of obstructive jaundice in adult patients with metastatic pancreatic carcinoma with an expected OS greater than 6 months was found to be a more cost-effective strategy than plastic stents. These results reinforce guidelines’ suggestions for metal stent placement.
Literatur
1.
Zurück zum Zitat Adams MA, Anderson MA, Myles JD, Khalatbari S, Scheiman JM. Self-expanding metal stents (SEMS) provide superior outcomes compared to plastic stents for pancreatic cancer patients undergoing neoadjuvant therapy. J Gastrointest Oncol. 2012;3(4):309–13.PubMedPubMedCentral Adams MA, Anderson MA, Myles JD, Khalatbari S, Scheiman JM. Self-expanding metal stents (SEMS) provide superior outcomes compared to plastic stents for pancreatic cancer patients undergoing neoadjuvant therapy. J Gastrointest Oncol. 2012;3(4):309–13.PubMedPubMedCentral
3.
Zurück zum Zitat Arguedas MR, Heudebert GH, Stinnett AA, Wilcox CM. Biliary stents in malignant obstructive jaundice due to pancreatic carcinoma: a cost-effectiveness analysis. Am J Gastroenterol. 2002;97(4):898–904.CrossRefPubMed Arguedas MR, Heudebert GH, Stinnett AA, Wilcox CM. Biliary stents in malignant obstructive jaundice due to pancreatic carcinoma: a cost-effectiveness analysis. Am J Gastroenterol. 2002;97(4):898–904.CrossRefPubMed
4.
Zurück zum Zitat Bakhru M, Ho HC, Gohil V, Wang AY, Ellen K, Sauer BG, Shami VM, Kahaleh M. Fully-covered, self-expandable metal stents (CSEMS) in malignant distal biliary strictures: mid-term evaluation. J Gastroenterol Hepatol. 2011;26(6):1022–7.CrossRefPubMed Bakhru M, Ho HC, Gohil V, Wang AY, Ellen K, Sauer BG, Shami VM, Kahaleh M. Fully-covered, self-expandable metal stents (CSEMS) in malignant distal biliary strictures: mid-term evaluation. J Gastroenterol Hepatol. 2011;26(6):1022–7.CrossRefPubMed
5.
Zurück zum Zitat Boston Scientific Corp. (2012) Procedural Reimbursment Guide. Effective 2012 Jan 1. ENDO-47410-AA JAN 2012. © 2012 Boston Scientific Corporation or its affiliates. All rights reserved. Boston Scientific Corp. (2012) Procedural Reimbursment Guide. Effective 2012 Jan 1. ENDO-47410-AA JAN 2012. © 2012 Boston Scientific Corporation or its affiliates. All rights reserved.
6.
Zurück zum Zitat Buxbaum JL, Biggins SW, Bagatelos KC, Inadomi JM, Ostroff JW. Inoperable pancreatic cancer patients who have prolonged survival exhibit an increased risk of cholangitis. JOP. 2011;12(4):377–83.PubMedPubMedCentral Buxbaum JL, Biggins SW, Bagatelos KC, Inadomi JM, Ostroff JW. Inoperable pancreatic cancer patients who have prolonged survival exhibit an increased risk of cholangitis. JOP. 2011;12(4):377–83.PubMedPubMedCentral
7.
Zurück zum Zitat Chen V, Arguedas M, Baron T. Expandable metal biliary stents before pancreaticoduodenectomy for pancreatic cancer: a Monte-Carlo decision analysis. Clin Gastro and Hepatology. 2005;3:1229–37.CrossRef Chen V, Arguedas M, Baron T. Expandable metal biliary stents before pancreaticoduodenectomy for pancreatic cancer: a Monte-Carlo decision analysis. Clin Gastro and Hepatology. 2005;3:1229–37.CrossRef
8.
Zurück zum Zitat Conroy T, Desseigne F, Ychou M, et al. Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25.CrossRefPubMed Conroy T, Desseigne F, Ychou M, et al. Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25.CrossRefPubMed
9.
Zurück zum Zitat Epstein AM, Jha AK, Orav EJ, Liebman DL, Audet AM, Zezza MA, Guterman S. Analysis of early accountable care organizations defines patient, structural, cost, and quality-of-care characteristics. Health Aff (Millwood). 2014;33(1):95–102.CrossRef Epstein AM, Jha AK, Orav EJ, Liebman DL, Audet AM, Zezza MA, Guterman S. Analysis of early accountable care organizations defines patient, structural, cost, and quality-of-care characteristics. Health Aff (Millwood). 2014;33(1):95–102.CrossRef
10.
Zurück zum Zitat Fagenholz P, Fernandez-del Castillo C, Harris N, et al. Direct medical costs of acute pancreatitis hospitalizations in the United States. Pancreas. 2007;35(4):302–7.CrossRefPubMed Fagenholz P, Fernandez-del Castillo C, Harris N, et al. Direct medical costs of acute pancreatitis hospitalizations in the United States. Pancreas. 2007;35(4):302–7.CrossRefPubMed
11.
Zurück zum Zitat Gómez-Oliva C, Guarner-Argente C, Concepción M, Jiménez FJ, Rodríguez S, Gonzalez-Huix F, Mugica F, Cabriada JL, Rodríguez C, Aguilar CG, Collaborating Group of the COBIWA Register. Partially covered self-expanding metal stent for unresectable malignant extrahepatic biliary obstruction: results of a large prospective series. Surg Endosc. 2012;26(1):222–9.CrossRefPubMed Gómez-Oliva C, Guarner-Argente C, Concepción M, Jiménez FJ, Rodríguez S, Gonzalez-Huix F, Mugica F, Cabriada JL, Rodríguez C, Aguilar CG, Collaborating Group of the COBIWA Register. Partially covered self-expanding metal stent for unresectable malignant extrahepatic biliary obstruction: results of a large prospective series. Surg Endosc. 2012;26(1):222–9.CrossRefPubMed
13.
Zurück zum Zitat Heiberg T, Nordby T, Kvien TK, Buanes T. Development and preliminary validation of the pancreatic cancer disease impact score. Support Care Cancer. 2013;21(6):1677–84.CrossRefPubMedPubMedCentral Heiberg T, Nordby T, Kvien TK, Buanes T. Development and preliminary validation of the pancreatic cancer disease impact score. Support Care Cancer. 2013;21(6):1677–84.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Howard K, Lord SJ, Speer A, Gibson RN, Padbury R, Kearney B. Value of magnetic resonance cholangiopancreatography in the diagnosis of biliary abnormalities in postcholecystectomy patients: a probabilistic cost-effectiveness analysis of diagnostic strategies. Int J Technol Assess Health Care. 2006;22(1):109–18.CrossRefPubMed Howard K, Lord SJ, Speer A, Gibson RN, Padbury R, Kearney B. Value of magnetic resonance cholangiopancreatography in the diagnosis of biliary abnormalities in postcholecystectomy patients: a probabilistic cost-effectiveness analysis of diagnostic strategies. Int J Technol Assess Health Care. 2006;22(1):109–18.CrossRefPubMed
15.
Zurück zum Zitat Jeurnink S, Steyerberg E, Kuipers E, et al. The burden of endoscopic retrograde cholangiopancreatography (ERCP) performed with the patient under conscious sedation. Surg Endosc. 2012;26:2213–9.CrossRefPubMed Jeurnink S, Steyerberg E, Kuipers E, et al. The burden of endoscopic retrograde cholangiopancreatography (ERCP) performed with the patient under conscious sedation. Surg Endosc. 2012;26:2213–9.CrossRefPubMed
16.
Zurück zum Zitat Khashab MA, Kim K, Hutfless S, et al. Predictors of early stent occlusion among plastic biliary stents. Dig Dis Sci. 2012;57(9):2446–50.CrossRefPubMed Khashab MA, Kim K, Hutfless S, et al. Predictors of early stent occlusion among plastic biliary stents. Dig Dis Sci. 2012;57(9):2446–50.CrossRefPubMed
17.
Zurück zum Zitat Krzyzanowska MK, Earle CC, Kuntz KM, Weeks JC. Using economic analysis to evaluate the potential of multimodality therapy for elderly patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2007;67(1):211–8.CrossRefPubMed Krzyzanowska MK, Earle CC, Kuntz KM, Weeks JC. Using economic analysis to evaluate the potential of multimodality therapy for elderly patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2007;67(1):211–8.CrossRefPubMed
18.
Zurück zum Zitat Loehrer Sr PJ, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, Flynn P, Ramanathan RK, Crane CH, Alberts SR, Benson 3rd AB. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2011;29(31):4105–12.CrossRefPubMedPubMedCentral Loehrer Sr PJ, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, Flynn P, Ramanathan RK, Crane CH, Alberts SR, Benson 3rd AB. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2011;29(31):4105–12.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat O’Neill CB, Atoria CL, O’Reilly EM, LaFemina J, Henman MC, Elkin EB. Costs and trends in pancreatic cancer treatment. Cancer. 2012;118(20):5132–9.CrossRefPubMedPubMedCentral O’Neill CB, Atoria CL, O’Reilly EM, LaFemina J, Henman MC, Elkin EB. Costs and trends in pancreatic cancer treatment. Cancer. 2012;118(20):5132–9.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Perry A, Dellon E, Lund J. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology. 2012;143:1179–87.CrossRef Perry A, Dellon E, Lund J. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology. 2012;143:1179–87.CrossRef
21.
Zurück zum Zitat Pola S, Muralimohan R, Cohen B, Fehmi SM, Savides TJ. Long-term risk of cholangitis in patients with metal stents for malignant biliary obstruction. Dig Dis Sci. 2012;57(10):2693–6.CrossRefPubMed Pola S, Muralimohan R, Cohen B, Fehmi SM, Savides TJ. Long-term risk of cholangitis in patients with metal stents for malignant biliary obstruction. Dig Dis Sci. 2012;57(10):2693–6.CrossRefPubMed
22.
Zurück zum Zitat Riall T, Zhang D, Townsend C. Failure to perform cholecystectomy for acute cholecystitis in elderly patients is associated with increased morbidity, mortality, and cost. J Am Coll Surg. 2010;5:668–77.CrossRef Riall T, Zhang D, Townsend C. Failure to perform cholecystectomy for acute cholecystitis in elderly patients is associated with increased morbidity, mortality, and cost. J Am Coll Surg. 2010;5:668–77.CrossRef
23.
Zurück zum Zitat Rombouts SJ. Walma MS, Vogel JA et al. Systematic review of resection rates and clinical outcomes after FOLFIRINOX-based treatment in patients with locally advanced pancreatic cancer. Ann Surg Oncol. 2016. Rombouts SJ. Walma MS, Vogel JA et al. Systematic review of resection rates and clinical outcomes after FOLFIRINOX-based treatment in patients with locally advanced pancreatic cancer. Ann Surg Oncol. 2016.
24.
Zurück zum Zitat Yoon WJ, Ryu JK, Yang KY, Paik WH, Lee JK, Woo SM, Park JK, Kim YT, Yoon YBA. Comparison of metal and plastic stents for the relief of jaundice in unresectable malignant biliary obstruction in Korea: an emphasis on cost-effectiveness in a country with a low ERCP cost. Gastrointest Endosc. 2009;70(2):284–9.CrossRefPubMed Yoon WJ, Ryu JK, Yang KY, Paik WH, Lee JK, Woo SM, Park JK, Kim YT, Yoon YBA. Comparison of metal and plastic stents for the relief of jaundice in unresectable malignant biliary obstruction in Korea: an emphasis on cost-effectiveness in a country with a low ERCP cost. Gastrointest Endosc. 2009;70(2):284–9.CrossRefPubMed
Metadaten
Titel
Cost Effectiveness of Metal Stents in Relieving Obstructive Jaundice in Patients with Pancreatic Cancer
verfasst von
J. M. Martinez
A. Anene
T. G. K. Bentley
M. J. Cangelosi
L. M. Meckley
J. D. Ortendahl
A. J. Montero
Publikationsdatum
27.12.2016
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Cancer / Ausgabe 1/2017
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-016-9907-4

Weitere Artikel der Ausgabe 1/2017

Journal of Gastrointestinal Cancer 1/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.